目的 探究硫普罗宁片联合恩替卡韦分散片治疗慢性乙型肝炎的临床疗效。方法 选取2014年3月-2016年11月于南充市中心医院收治的HBeAg阳性慢性乙型肝炎患者94例，按随机数字表法分为对照组和治疗组，每组各47例。对照组患者口服恩替卡韦分散片，0.5 mg/次，1次/d，治疗组在对照组治疗的基础上口服硫普罗宁片，0.1 g/次，3次/d。两组均连续治疗6个月。观察两组的临床疗效，比较两组肝功能指标、炎症因子水平和血清病毒学指标。结果 治疗后，对照组总有效率78.72%，明显低于治疗组的93.62%，两组比较差异具有统计学意义（P<0.05）。治疗3、6个月后，两组血清丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、总胆红素（TBIL）水平均明显下降，血清白蛋白水平明显升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组与对照组同期比较差异有统计学意义（P<0.05）。治疗3、6个月后，两组血清白介素（IL）-2、肿瘤坏死因子（TNF）-α水平均明显下降，血清白介素（IL）-10水平明显升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组与对照组同期比较差异具有统计学意义（P<0.05）。对照组HBV-DNA阴转率为55.32%，HBeAg阴转率为40.43%，HBeAg转换率为34.04%；治疗组HBV-DNA阴转率59.57%，HBeAg阴转率为38.30%，HBeAg转换率为31.91%，两组血清病毒学指标比较差异无统计学意义。结论 硫普罗宁片联合恩替卡韦分散片治疗慢性乙型肝炎具有较好的临床疗效，能有效改善肝功能，缓解炎症因子紊乱，具有一定的临床推广应用价值。

Objective To investigate the effect of Tiopronin Tablets combined with Entecavir Dispersible Tablets in treatment of chronic hepatitis B. Methods Patients (94 cases) with HBeAg-positive chronic hepatitis B in Nanchong Central Hospital from March 2014 to November 2016 were divided into control and treatment groups by random number table method, and each group had 47 cases. Patients in the control group were po administered with Entecavir Dispersible Tablets, 0.5 mg/time, once daily. Patients in the treatment group were po administered with Tiopronin Tablets on the basis of the control group, 0.1 g/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the liver function indexes, inflammatory cytokines, and serum virology indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.72%, which was significantly lower than 93.62% in the treatment group, and there were differences between two groups (P<0.05). After treatment for 3 or 6 months, the levels of ALT, AST, and TBIL in two groups were significantly decreased, but the serum albumin levels in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the liver function indexes in the treatment group were significantly better than those in the control group in the same period, with significant difference between two groups (P<0.05). After treatment for 3 or 6 months, the levels of serum IL-2 and TNF-α in two groups were significantly decreased, but the levels of serum IL-10 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory cytokines in the treatment group were significantly better than those in the control group in the same period, with significant difference between two groups (P<0.05). The negative conversion rate of HBV-DNA, the negative conversion rate of HBeAg, and the conversion rate of HBeAg in the control group were 55.32%, 40.43%, and 34.04%, respectively, and those in the treatment group were 59.57%, 38.30%, and 31.91%, but there was no statistically significant difference between two groups. Conclusion Tiopronin Tablets combined with Entecavir Dispersible Tablets has good clinical effect in treatment of chronic hepatitis B, can significantly improve liver function and inflammatory factor disorder, which has a certain clinical application value.